Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 13Thoracic 4Head & Neck 4Genitourinary 4Breast 4Gynecologic 3Sarcoma 2Plasma cell 1NET 1Endocrine 1Dermatologic 1CNS 1

Conditions

Neuroendocrine Tumors 43Carcinoma, Neuroendocrine 8Gastro-enteropancreatic neuroendocrine tumor 7Sarcoma 6Carcinoid Tumor 6Stomach Neoplasms 5Small Cell Lung Carcinoma 5Paraganglioma 5Neoplasms 5Prostatic Neoplasms 4Pheochromocytoma 4Neoplasm Metastasis 4Lung Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Carcinoma 4Thyroid Neoplasms 3Neuroblastoma 3Carcinoma, Renal Cell 3Thyroid Diseases 2Thoracic Neoplasms 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Ovarian Neoplasms 2Neuroectodermal Tumors 2Neoplasms, Germ Cell and Embryonal 2Neoplasms by Site 2Neoplasms by Histologic Type 2Meningioma 2Medulloblastoma 2

Interventions

tivozanib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Gallbladder Neoplasms × NET × Clear all
NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Suspended
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡